Tirzepatide Offers Potential Alternative to Daily Hormone Shots for Rare Genetic Fat Disorder
A groundbreaking study suggests that a once-weekly injection of tirzepatide could revolutionize treatment for patients with congenital generalized lipodystrophy (CGL), a rare genetic disorder characterized by the near-complete absence of fat tissue from birth. This innovative approach may replace the current standard-of-care, which involves daily injections of metreleptin, a synthetic form of the hormone leptin. … Read more